U
se of complementary and alternative medicine (CAM) to treat psychiatric problems is widespread, and the need has been identified for more high-quality controlled trials. A task force of the American Psychiatric Association concluded that several CAM treatments, including omega-3 fatty acids, St John's wort, folate, acupuncture, and others, show promise for depression, but that more rigorous and larger studies were needed. 1 A meta-analysis by Freeman et al 2 reported comparable efficacy but greater safety for a number of herbal and dietary supplements than for standard antidepressants. Among the many forms of CAM, homeopathy is one of the most widely used on a global basis. 3 Meta-analyses and systematic reviews have drawn mixed conclusions as to whether homeopathy is more effective than placebo in general medicine. [4] [5] [6] [7] [8] [9] [10] In assessing these studies, Lewith 7 has pointed out that where reports are few and based on small samples, results of systematic reviews depend on which studies are included and which are excluded. Thus, any fair assessment needs to be systematic and comprehensive and use established quality and scoring approaches on all studies. No comprehensive review of research on homeopathy for psychiatric conditions has been conducted. Our aim in this article was to undertake such a systematic review.
Although widely used in many parts of the world, homeopathy remains controversial within the Western medical paradigm. This is due principally to discordance between the principles of homeopathy and those of accepted biomedical theory. The system of homeopathy rests on 2 fundamental principles: (1) similarity, whereby the indicated remedy for particular symptoms is that which elicits similar symptoms when given to a healthy person, and (2) the power of the minimum dose, whereby a substance that is repeatedly diluted and agitated ("succussed") is believed to preserve its effect even into "ultramolecular" solutions. 4 In all major reviews of homeopathy, there is an absence of comprehensive reviews of studies relevant to psychiatry, even though there are some encouraging findings. For example, in one review homeopathy was superior to placebo on at least 1 clinically meaningful measure in 6 of 7 trials of fibromyalgia, anxiety, agitation, traumatic brain injury (TBI), and premenstrual syndrome (PMS). 9 On the other hand, a Cochrane review of attention-deficit/hyperactivity disorder (ADHD) showed no overall benefit for homeopathy over placebo in 3 randomized clinical trials. 11 Two systematic reviews in depression 12 and anxiety 13 found insufficient good quality data to judge the efficacy of homeopathy for these conditions. A Cochrane review of homeopathy for dementia found no placebo-controlled studies of adequate quality.
14 Evidence in support of homeopathy for fibromyalgia is more encouraging, Because patients with psychiatric problems are well represented in homeopathic practice, 18, 19 it is important to examine whether homeopathy is beneficial in the more commonly seen psychiatric conditions, defined here as anxiety, depression, sleep problems, ADHD, PMS, mild TBI, and somatic spectrum disorders.
Our objective was to conduct a comprehensive, systematic literature review of placebo-controlled, randomized clinical trials of homeopathy for psychiatric conditions, to assess the quality and risk of bias in each study's design and execution, to report on outcome when possible by means of effect size (ES) or number needed to treat (NNT) statistics, to review safety, and to grade the overall evidence for each condition according to internationally standardized methods. Because of the heterogeneity of studies in each psychiatric category, we did not undertake meta-analysis of the data but did check for likelihood of publication bias in a subset of the data.
METHOD Data Sources and Search Strategy
A systematic search was conducted for literature that described homeopathic treatment of the following 7 groups of psychiatric conditions: depression, anxiety, sleep and circadian rhythm problems, ADHD, PMS, mild TBI, and functional somatic syndromes (FSS), specifically fibromyalgia and chronic fatigue syndrome. The following databases were examined for studies reported from database inception to April 2010: PubMed, CINAHL, PsycINFO, Hom-Inform, Cochrane CENTRAL, National Center for Complementary and Alternative Medicine grantee publications database, and ClinicalTrials.gov. Gray literature was also searched using Google, Google Scholar, the European Committee for Homeopathy, inquiries with homeopathic experts and manufacturers, and the bibliographic lists of included studies and published reviews. Search terms used were as follows: (homeopath* or homoeopath*) and (placebo or sham) and (anxiety or panic or phobia or post-traumatic stress or PTSD or obsessive-compulsive disorder or fear or depress* or dysthym* or attention deficit hyperactivity or premenstrual syndrome or premenstrual disorder or premenstrual dysphoric disorder or traumatic brain injury or fibromyalgia or chronic fatigue syndrome or myalgic encephalitis or insomnia or sleep disturbance). The following limits were placed on searches: only literature presented in the English language that reported randomized controlled trials (RCTs) in human subjects. All searches were performed across titles/abstracts where possible. Where some of these restrictions were not possible, we screened the titles and abstracts manually.
Inclusion and Exclusion Criteria
Four investigators (C.C., J.A.I., W.B.J., and J.R.T.D.) independently screened titles and abstracts for relevance based on the inclusion criteria for this systematic review. Any disagreements about including a study were resolved through discussion and consensus. Articles were included in this systematic review if they met the following criteria: (1) randomized controlled trial (RCT) design was used; (2) a placebo control was used; (3) between-treatment comparisons were made of homeopathic treatment versus placebo; (4) treatment was given in a double-blind fashion; (5) the report assessed a psychiatric condition as specified in the keyword list above; (6) the report was presented in English; and (7) the study involved treatment-seeking human subjects; that is, we did not review any animal model studies, studies in healthy volunteers, or studies in patient groups in which the focus was on mechanism of action or prediction of treatment effect.
Quality Rating of Individual Studies
Methodological quality of the included studies was assessed independently by the 4 reviewers for the individual studies and then by 2 reviewers (W.B.J. and J.R.T.D.) on the quality of the overall literature pool with regard to the minimization of bias. The individual studies were all RCTs and were evaluated for study quality and bias using the Scottish Intercollegiate Guidelines Network (SIGN) 50 checklist for RCTs.
20 SIGN is an internationally developed and accepted assessment approach widely used for both conventional and complementary medicine research. Once the quality assessment of the individual studies was completed, 2 reviewers conducted a quality assessment of the overall literature pool for each condition using the Grading of Recommendations Assessment, Development and Evaluation (GRADE), looking at the (1) confidence in the estimate of the ES, (2) magnitude of the effect, (3) safety grade, and (4) strength of the recommendation. 21 GRADE is also an internationally accepted approach for quality assessment of literature sets.
All reviewers were trained in the quality assessment of individual studies (SIGN) and the quality assessment of overall literature pool (GRADE) by 1 of the authors (C.C.), and each article was assessed by 2 reviewers. For any discrepancies, discussion occurred between reviewers in order to
Clinical Points
Randomized placebo-controlled studies suggest that ■ homeopathy is without benefit for anxiety, that it may be useful for functional somatic syndromes, and that for other conditions such as ADHD, premenstrual and sleep-related problems, its benefit is undetermined. For other common psychiatric conditions such as depression, posttraumatic stress disorder, and dementia, there are no informative data.
Although homeopathic medicines are well tolerated and ■ believed to carry few side effects, there has to date been no adequate demonstration of their safety.
It is unknown whether a single individually chosen ■ medicine is more effective than a fixed-dose combination formula. J Clin Psychiatry 72:6, June 2011 achieve consensus. Final judgment was reserved for the first author (J.R.T.D.).
Data Analysis
For every study that provided a mean score and SD, SE, t, or F statistic, we calculated the ES between treatments using the Hedges unbiased g, 22 which mathematically adjusts for small samples. The ES was recorded as positive if it favored homeopathy and negative if placebo was more effective. Consistent with the GRADE conventions, an ES that ranges from 0.20 to 0.49 is considered to be small, 0.50 to 0.79 is medium, and 0.8 or greater is large. For studies reporting rates of response, the NNT was calculated. 23 For a subset of 13 studies that gave sufficient information to derive ES and the 95% CIs, we calculated an estimate for possible publication bias by graphing the 1/var to g and running the nonparametric selection model applied to the 13 studies. 3 The outcome measures chosen for calculating ES were those identified in the respective publications as primary. When more than 1 primary measure was identified and results were conflicting, ES were calculated separately for the most and least favorable toward homeopathy. In studies in which primary outcomes uniformly failed to show a statistically significant difference, a single scale was chosen at random.
In some cases, as shown in the tables, a study appeared more than once, usually because it was published as a thesis at a university Web site, and elsewhere as a peer-reviewed publication. SIGN ratings were conducted on each communication and on the combination, assigning the higher ratings (if they differed) if one report gave more complete information than the other; the overall evaluation was based on information from both.
RESULTS

Study Selection and Quality
The search strategy led to the identification of 69 reports from online databases (Hom-Inform, n = 29; ClinicalTrials. gov, n = 1; MEDLINE [PubMed], n = 14; PsycINFO, n = 6; Cochrane CENTRAL, n = 19; CINAHL, n = 0), 836 from other sources (n = 834 from the following sources: European Committee for Homeopathy List of Dissertations and Theses in Homeopathy, n = 644; theses and dissertations from Durban University of Technology [Health Sciences], n = 66; and theses and dissertations from University of Johannesburg, n = 124; plus reference mining, n = 2), and 526 from 10 systematic reviews ( Figure 1 ). As shown in Table 1 , 25 studies fulfilled the specified criteria. According to SIGN quality analysis, 6 studies were rated as "good" (++) with respect to minimizing bias, 9 as "fair" (+), and 10 as "poor" (-). These are shown individually in eAppendix 1.
Of the 25 studies, 6 were conducted in populations suffering from anxiety or stress; 5, in subjects with sleep or circadian rhythm disturbances; 4, in subjects with premenstrual problems; 3, in subjects with ADHD; 1, in subjects with mild TBI; and 6, in subjects with functional somatic syndromes. 
HARS (NS) BAI (NS) PPQ (NS)
Not given A proven treatment for GAD, cognitive therapy, failed to work; study can be regarded as a "failed" study rather than a negative study for homeopathy. 
Table 1 (continued). Placebo-Controlled, Randomized Clinical Trials of Homeopathy for Common Psychiatric Conditions: Quality of Individual Studies
Relevant details of these studies are shown in Tables  1 and 2 . No placebo-controlled studies of depression were identified. Table 1 presents details of each study, and Table  2 presents the overall GRADE assessment. Taking a statistically significant P value as a crude indicator of possible efficacy, the following assessment for each condition was found:
There is no support for the efficacy of home-• opathy in anxiety-or stress-related conditions. In only 1 study, 27 on a sleep measure, did the difference reach significance. For sleep-and circadian rhythm-related • problems, the evidence is mixed. Two studies 30, 31 yielded predominantly positive results, and these were the studies that scored higher on GRADE evaluation (Table 2) . Because each study addressed a different problem, however, we do not think the cumulative evidence for any one condition warrants either a positive or a negative overall recommendation for this group. For premenstrual problems, there was little • evidence of efficacy, other than 1 suggestive study, 38 which was limited by a small sample size. Of 3 ADHD studies, 1 relapse prevention • design was positive, 42 and 2 acute symptom reduction trials were negative, 41, 43, 44 although the report by Strauss 43 indicated statistical significance on 1 measure. Two 41, 42 of the 3 ADHD studies scored strongly on SIGN evaluation. For mild TBI, the 1 available study • 45 scored favorably on attempts to reduce bias and produced weakly positive results in favor of homeopathy. Of 6 FSS studies, • 46-51 all except 1 yielded positive evidence that homeopathy was superior to placebo, and the negative study 51 was one of the smallest and methodologically the weakest. Fisher's first study 46 failed to show positive effect for homeopathy on the all-comers sample but was positive on 2 key predefined measures when prospective matching of remedy to clinical picture was taken into account. His second study 47 was positive on 1 measure, but impossible to interpret on 2 of the 4 primary outcomes. 52, 53 Three positive FSS trials [46] [47] [48] were given low ratings according to the SIGN and GRADE assessments, but the 2 methodologically strongest studies 49, 50 were positive for homeopathy. In one of these, 49 although several outcomes failed to show a difference, the most rigorous measure of clinically significant improvement in all primary scales was positive. J Clin Psychiatry 72:6, June 2011 Magnitude of the effect size. We categorize this data element into 4 levels (none, small, moderate, and large). We attempted to calculate effect size for the studies meeting inclusion criteria if an effect size was not provided. We report how many studies reported a small effect (0.2-0.5), moderate (0.5-0.8), and large (> 0.8) effect. We also report the number of studies from which we were not able to calculate an effect size. Safety GRADE. Formulating the safety grade is dependent on the frequency and severity of adverse effects and interactions. The criteria developed are as follows: +2 = appears safe with infrequent adverse events and interactions, +1 = appears relatively safe but with frequent but not serious adverse events and interactions, 0 = safety not well understood or conflicting, -1 = appears to have safety concerns that include infrequent but serious adverse events and/or interactions, and -2 = has serious safety concerns that include frequent and serious adverse events and/or interactions. Strength of the recommendation. GRADE has defined the levels as follows: strong recommendation in favor, weak recommendation in favor, no recommendation, weak recommendation against, and strong recommendation against.
Abbreviation: GRADE = Grading of Recommendations Assessment, Development and Evaluation.
Effect Size and Number Needed to Treat It was possible to calculate ESs in 16 of the 25 studies. Of the 12 studies in which a single outcome was used to determine ES, results favored homeopathy in 8 and placebo in 4 cases; The magnitude of effect in favor of homeopathy was large in 2, medium in 1, small in 2, and negligible in 3. ES in favor of placebo was small in 1 study and below 0.2 in 3 studies. For the 4 studies with multiple primary outcomes that yielded discrepant results, the most favorable ES for homeopathy was medium in 1 study and small in 3 studies. For those outcomes least favorable to homeopathy, the ES was small in 2 cases and negligible (ie, below 0.2) in 2 cases. Across the 13 studies in which it was possible to obtain confidence intervals for the ES, the upper and lower bounds of 95% confidence intervals crossed zero in all except 3 instances, thus indicating substantial imprecision in the estimates of treatment effect, which are shown in Table 3 .
In 10 studies, it was possible to obtain response rates and derive the NNTs, which are given by category. NNT results were obtained for 4 of the 6 FSS studies, [47] [48] [49] [50] which when pooled (N = 260) yield an NNT of 3.67.
The chance of obtaining a positive result favoring homeopathy was unrelated to study quality. Quality of the 25 studies was variable with respect to minimization of bias, but there was no suggestion that the more favorable outcomes for homeopathy were associated with lower quality or weaker methodology, in that a higher proportion (66%) of the 6 best-quality reports could be taken as supportive of homeopathy to varying degrees, while only 4 of 10 (40%) in the weakest group provided positive evidence. This lack of association between quality and outcome is possibly due to the low number of studies for which ES could be calculated (16) , the rather crude nature of quality rating schemes in general, and the small sample sizes, which have a large impact on estimates of precision. Publication bias is another possible reason, with lowerquality studies simply not being published or reported. We doubt that publication bias was a significant factor, however, because of our extensive search strategy, the inclusion of "gray" literature, and the generally low level of funding for research in this field. In addition, we conducted a funnel plot using 13 studies with sufficient information for this procedure (data not shown). Analysis of J Clin Psychiatry 72:6, June 2011 the funnel plot also did not support evidence of publication bias (χ 2 1 = 1.923, P = .166).
DISCUSSION
Principal findings of this systematic review are as follows: Homeopathy had no effect over placebo in the studies of anxiety and stress reaction. There are currently no studies meeting our selection criteria for depression. There was reasonable evidence for the efficacy of homeopathy in functional somatic syndromes. Findings for other conditions were mixed and inconclusive. Sample sizes were generally small, and overall confidence in the results was graded as moderate or low, suggesting that further research could well change the estimate of effect. Mainly because of the limited number of studies in any single category and heterogeneity of the data set, we decided that meta-analysis was not meaningful. Disorders were grouped to provide some level of diagnostic homogeneity, although this clearly worked better for some disorders (eg, ADHD, PMS) than for others (eg, sleep/ circadian rhythm and anxiety disorders). Possible reasons for the lack of effect in stress and anxiety include a high placebo response or spontaneous recovery for the conditions studied, clinical variability of the included syndromes, methodological problems, or some other factor. Further study of homeopathy in sleep-related disorders is warranted; a recent polysomnography study by Bell et al 54 offers some basis for believing in the activity of homeopathic remedies on sleep mechanisms. The efficacy of homeopathy for FSS looks promising, but larger well-designed studies are needed.
Functional somatic syndromes, which account for 25% to 50% of all outpatient visits in the United States, 55 are chronic, disabling conditions that are unlikely to show spontaneous improvement. They are also among the more frequently studied psychiatric disorders with respect to homeopathy. In this review, 5 of the 6 studies provided some evidence for efficacy in either fibromyalgia or chronic fatigue syndrome. The low placebo response (4%-15%) and modestly consistent rates of response to homeopathy (26%-50%) in these disorders and the larger sample size of over 200 patients may have yielded more precise estimates than in the other categories. Taking the best-case outcomes, ESs of 0.31 (pain) and 0.40 (fatigue) are comparable to the ES ranges that have been reported for selective serotonin reuptake inhibitor antidepressants of 0.39 and 0.17. 56 Other widely used psychotropic drugs for fibromyalgia have small ESs for pain and fatigue, in the range of 0.2 for pain and 0.1 to 0.3 for fatigue. 57 Consistent with the efficacy of homeopathy in fibromyalgia is a pragmatic RCT that showed benefit for homeopathy over usual treatment in primary care. 58 Relevant collateral support in this context comes from exploratory work by Bell et al, 59 ,60 who found links of clinical benefit to possible mechanisms of action and predictors of response in their fibromyalgia sample. The overall NNT for homeopathy on global measures in the 4 studies that provided source information compares favorably with the NNTs of 5.0 to 9.2 (as determined for 30% relief of pain) reported in 5 studies of gabapentin and pregabalin for fibromyalgia. 57 All-cause dropout rates in 3 FSS studies were 11% for homeopathy and 10% for placebo, which compares to the published dropout rate of 21% for adverse effects with pregabalin and gabapentin. 57 As noted by others, 15,16 studies of homeopathy for fibromyalgia are currently neither sufficiently rigorous nor sufficiently plentiful to warrant a definite answer on its use, but the evidence is encouraging.
Full understanding of any treatment involves not only evidence of efficacy, but also evidence of safety. Unfortunately, only 7 studies addressed this question, and even then the assessments were minimal, but all indicated there was no difference between homeopathy and placebo, which is consistent with the general presumption about the safety of homeopathy, where side effects and aggravations of the underlying symptoms have not been found to occur more frequently on homeopathy than on placebo in a major systematic analysis. 61 In one study of ADHD, 42 there were 3 dropouts related to tics, depression, and disturbed behavior, which suggests that careful evaluations might indicate the existence of homeopathy-related adverse effects. What cannot be assessed here, however, is the "harm" caused by failing to offer an effective treatment to a condition that, if untreated, leads to disability or other morbidity. To the extent that the reports said little about safety, our GRADE-based recommendations have limitations, since safety evaluation should be taken into account when making such assessments. One surprising finding was the low rate of dropouts, which was 12% in 12 studies (range, 0%-21%). In that one of the more common reasons for early exit relates to side effects, a low dropout rate might be seen as a favorable aspect of homeopathic treatment. On the other hand, an almost total lack of side effects is often taken to imply lack of efficacy. This aspect of homeopathy has consistently been neglected in the design and reporting of clinical trials.
Limitations of this review include its inability to provide information about major depression, which is such a large health problem worldwide and for which there is quite an extensive literature on other CAM approaches. We also did not include the entire range of psychiatric problems in our review, such as dementia, alcohol and substance problems, eating disorders, or psychosis. Apart from an unrevealing Cochrane review of homeopathy for dementia, we are unaware of any systematic reviews, or even a double-blind placebo-controlled trial, of homeopathy in any of these disorders. Another consideration is that not all studies we reviewed presented their results as an intent-to-treat analysis.
In summary, our review demonstrates that well-designed and comprehensively reported homeopathic studies in psychiatry are few and far between and preclude firm conclusions about the efficacy of this treatment in any single disorder.
The same holds true for safety. For anxiety and stress-related problems, particularly generalized anxiety disorder, the data are not encouraging, but most forms of anxiety remain unstudied. For fibromyalgia and chronic fatigue syndrome as a group, results suggest possible utility for homeopathy. For the other disorders, the data are insufficient in quality or quantity to generate either positive or negative recommendations. Overall, we believe the findings offer sufficient grounds to warrant further clinical trials and are compatible with the use of homeopathy to treat certain conditions. Where ratings were done of published, unpublished, and composite of both, the sequence was published report, unpublished thesis, and composite. Abbreviations: A = adequately addressed, N = not applicable, P = poorly addressed, PMS = premenstrual syndrome, SIGN = Scottish Intercollegiate Guidelines Network, TBI = traumatic brain injury, W = well addressed.
